Lyra Therapeutics Inc (LYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lyra Therapeutics Inc (LYRA) has a cash flow conversion efficiency ratio of 0.566x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.07 Million) by net assets ($-10.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lyra Therapeutics Inc (LYRA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Lyra Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Lyra Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lyra Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lyra Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Frontier Resources Corporation
V:IFR
|
0.017x |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
-0.001x |
|
Wynnstay Group Plc
LSE:WYN
|
0.178x |
|
Venture Life Group PLC
LSE:VLG
|
-0.012x |
|
Rare Foods Australia Ltd
AU:RFA
|
-0.026x |
|
BIOCURE TECHNOLOGY INC.
F:1WH
|
-0.005x |
|
Tearlach Resources Ltd
V:TEA
|
-0.043x |
|
Queste Communications Ltd
AU:QUE
|
-0.039x |
Annual Cash Flow Conversion Efficiency for Lyra Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lyra Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Lyra Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.72 Million | $-28.86 Million | 2.693x | +144.59% |
| 2024-12-31 | $11.59 Million | $-70.01 Million | -6.039x | -752.98% |
| 2023-12-31 | $89.42 Million | $-63.30 Million | -0.708x | -31.77% |
| 2022-12-31 | $80.75 Million | $-43.38 Million | -0.537x | +28.60% |
| 2021-12-31 | $34.32 Million | $-25.82 Million | -0.752x | -165.10% |
| 2020-12-31 | $74.49 Million | $-21.14 Million | -0.284x | +84.88% |
| 2019-12-31 | $7.33 Million | $-13.75 Million | -1.877x | -3126.63% |
| 2018-12-31 | $-107.07 Million | $-6.64 Million | 0.062x | -- |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more